Payment overview · 2025
General Payments
$284.40
11 reported records · 5 companies
Healthcare provider profile · identity verified
Sean Warren, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LOUISVILLE, KY · NPI 1063808137
Verified facts
What the public records show
CMS Open Payments records show Sean Warren, M.D. received $284.40 in general payments during 2025 across 11 reported records.
Eisai Inc. accounted for 59.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Eisai Inc. | Unresolved — no canonical attribution shown | $169.03 | 59.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.13 | 14.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.21 | 12.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.63 | 7.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.40 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $284.40 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $169.03 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $40.13 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.21 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.63 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.40 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.40 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 80 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
59 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 674 | 195 |
| Levothyroxine Sodium | Levothyroxine Sodium | 282 | 78 |
| Losartan Potassium | Losartan Potassium | 252 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 251 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 220 | 63 |
| Simvastatin | Simvastatin | 207 | 57 |
| Metformin Hcl | Metformin Hcl | 180 | 49 |
| Lisinopril | Lisinopril | 173 | 46 |
| Omeprazole | Omeprazole | 171 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 171 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 48 |
| Gabapentin | Gabapentin | 141 | 50 |
| Prednisone | Prednisone | 136 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 130 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 37 |
| Mirtazapine | Mirtazapine | 124 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 98 | 43 |
| Furosemide | Furosemide | 97 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 92 | 26 |
| Alendronate Sodium | Alendronate Sodium | 91 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 34 |
| Sertraline Hcl | Sertraline Hcl | 89 | 29 |
| Allopurinol | Allopurinol | 88 | 27 |
| Montelukast Sodium | Montelukast Sodium | 85 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 27 |
| Ozempic | Semaglutide | 80 | 16 |
| Carvedilol | Carvedilol | 77 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 22 |
| Clonazepam | Clonazepam | 74 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 22 |
| Eliquis | Apixaban | 70 | 21 |
| Potassium Chloride | Potassium Chloride | 64 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 62 | 17 |
| Synthroid | Levothyroxine Sodium | 59 | 16 |
| Azithromycin | Azithromycin | 58 | 39 |
| Ezetimibe | Ezetimibe | 55 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 13 |
| Warfarin Sodium | Warfarin Sodium | 49 | 11 |
| Lovastatin | Lovastatin | 47 | 11 |
| Alprazolam | Alprazolam | 46 | 13 |
| Baclofen | Baclofen | 45 | 13 |
| Levofloxacin | Levofloxacin | 45 | 36 |
| Bupropion Xl | Bupropion Hcl | 42 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 11 |
| Trazodone Hcl | Trazodone Hcl | 41 | 14 |
| Diazepam | Diazepam | 40 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 12 |
| Metformin Hcl Er | Metformin Hcl | 40 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | 13 |
| Jardiance | Empagliflozin | 37 | 12 |
| Fluconazole | Fluconazole | 36 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 36 | 36 |
| Famotidine | Famotidine | 35 | 15 |
| Spironolactone | Spironolactone | 35 | 11 |
| Glipizide | Glipizide | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Irbesartan | Irbesartan | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Cefdinir | Cefdinir | 28 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | 11 |
| Colestipol Hcl | Colestipol Hcl | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 11 |
| Glimepiride | Glimepiride | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Testosterone | Testosterone | 19 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | 11 |
| Telmisartan | Telmisartan | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $284.40 · 11 records | Eisai Inc. | FREESTYLE LIBRE 3, Leqembi, OTEZLA, Ozempic, REPATHA, Rybelsus, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error